RTI International Invests in Navidence to Standardize Real-World Evidence Definitions
Event summary
- RTI International has made a strategic equity investment in Navidence, a health data standardization company, on May 5, 2026.
- The partnership aims to standardize disease, treatment, and outcome definitions in real-world evidence (RWE) generation.
- Navidence's AI-native platform uses Computable Operational Definitions (CODefs) to streamline clinical research protocols.
- RTI's investment follows prior commitments to Nested Knowledge, b.well Connected Health, and BEK Health in evidence generation technologies.
The big picture
The partnership addresses a critical gap in life sciences research: the lack of standardized definitions for diseases, treatments, and outcomes in real-world evidence generation. RTI's investment reflects a broader industry shift toward AI-driven solutions that enhance research efficiency and reproducibility. With billions spent annually on research built on inconsistent data, this collaboration could set a new industry standard for evidence-based decision-making.
What we're watching
- Adoption Pace
- How quickly life sciences organizations will integrate Navidence's CODefs into their research workflows.
- Competitive Response
- Whether existing RWE platforms will develop competing standardization solutions.
- Regulatory Impact
- The extent to which standardized definitions influence regulatory decision-making for drug approvals.
Related topics